Tina Baykaner is a Cardiology physician. OpenAlex indexes 256 publications with 3,036 citations (h-index 25); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
300 Pasteur Dr
Stanford, CA 943052200
Telephone
650-723-4000Provider last certified this registry record 17 Apr 2024.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boston Scientific CorporationProgram year202525 payments$25,352openpaymentsdata.cms.gov ↗
- Medtronic, Inc.Program year202538 payments$15,108openpaymentsdata.cms.gov ↗
- Abbott LaboratoriesProgram year202512 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
57.7%Antiarrhythmic29.6%Flecainide Acetate62%Amiodarone Hcl27%Mexiletine Hcl11%Part D<11 patientsBeta blocker28.1%Metoprolol Succinate76%Carvedilol14%Metoprolol Tartrate10%Part D<11 patientsBlood & clotting
30.8%Factor Xa inhibitor30.8%Eliquis84%Xarelto16%Part D<11 patientsMetabolism & gastrointestinal
11.5%Aluminum Complex6.2%Sucralfate100%Part D≥26 patientsProton pump inhibitor5.3%Pantoprazole Sodium100%Part D≥22 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2019–2026 per NIH RePORTER. The latest:
- Atrial Fibrillation Among Patients with Hematologic Malignancies on Tyrosine Kinase Inhibitor Therapy
Stanford University
FY2026$743,696R01HL179128
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation
Journal of Interventional Cardiac Electrophysiology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”